Core Viewpoint - Tianyan Pharmaceuticals (ADAG) is a biopharmaceutical company focused on developing innovative cancer immunotherapies based on original antibodies, utilizing a powerful platform that combines computational biology and artificial intelligence [1]. Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, a year-over-year decrease of 99.43% [1]. - The company recorded a net profit attributable to shareholders of -$33,424,100, reflecting a year-over-year decline of 76.41% [1]. Company Overview - Tianyan Pharmaceuticals is a platform-driven biopharmaceutical company in the clinical product development stage, dedicated to discovering and developing new cancer immunotherapies [1]. - The company’s antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, aiming to create potentially innovative or best-in-class products globally [1].

Core Viewpoint - Tianyan Pharmaceutical (ADAG) is a biopharmaceutical company focused on developing innovative cancer immunotherapies based on original antibodies, utilizing a powerful platform that combines computational biology and artificial intelligence [1]. Financial Performance - As of December 31, 2024, Tianyan Pharmaceutical reported total revenue of $103,200, a year-over-year decrease of 99.43% [1]. - The company recorded a net profit attributable to shareholders of -$33,424,100, reflecting a year-over-year decline of 76.41% [1]. Company Overview - Tianyan Pharmaceutical is a platform-driven company engaged in the clinical product development phase, dedicated to discovering and developing new cancer immunotherapies [1]. - The company’s antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, aiming to create potentially innovative or best-in-class products globally [1].

Core Viewpoint - Tianyan Pharmaceuticals (ADAG) is a biopharmaceutical company focused on developing innovative cancer immunotherapies based on original antibodies, utilizing a powerful platform that combines computational biology and artificial intelligence [1]. Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, a year-over-year decrease of 99.43% [1]. - The company recorded a net profit attributable to shareholders of -$33,424,100, reflecting a year-over-year decline of 76.41% [1]. Company Overview - Tianyan Pharmaceuticals is a platform-driven biopharmaceutical company in the clinical product development stage, dedicated to discovering and developing new cancer immunotherapies [1]. - The company’s antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, aiming to create potentially innovative or best-in-class products globally [1].

财务数据显示，截至2024年12月31日，天演药业收入总额10.32万美元，同比减少99.43%；归母净利 润-3342.41万美元，同比减少76.41%。 资料显示，天演药业公司(纳斯达克股票代码:ADAG)是平台驱动并拥有自主平台产出的临床产品开发阶 段的生物制药公司,公司致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。借助计算生物学和 人工智能相结合的强大平台,公司研制出高安全性和有效性的新型抗体,为更多癌症患者带来了福音。公 司的抗体发现引擎——"动态精准抗体库"(Dynamic Precision Library),正在推动天演药业的产品管线开发, 致力于打造潜在的全球创新或同类最佳型产品。 本文源自：金融界 8月14日，天演药业(ADAG)盘中上涨20.61%，截至21:52，报1.99美元/股，成交9516.0美元，总市值 9379.12万美元。 作者：行情君 ...

本文源自：金融界 作者：行情君 财务数据显示，截至2024年12月31日，天演药业收入总额10.32万美元，同比减少99.43%；归母净利 润-3342.41万美元，同比减少76.41%。 资料显示，天演药业公司(纳斯达克股票代码:ADAG)是平台驱动并拥有自主平台产出的临床产品开发阶 段的生物制药公司,公司致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。借助计算生物学和 人工智能相结合的强大平台,公司研制出高安全性和有效性的新型抗体,为更多癌症患者带来了福音。公 司的抗体发现引擎——"动态精准抗体库"(Dynamic Precision Library),正在推动天演药业的产品管线开发, 致力于打造潜在的全球创新或同类最佳型产品。 8月13日，天演药业(ADAG)盘中上涨10.47%，截至21:51，报2.11美元/股，成交1.46万美元，总市值 9944.70万美元。 ...

Core Viewpoint - Tianyan Pharmaceuticals (ADAG) is a biopharmaceutical company focused on developing innovative cancer immunotherapies based on original antibodies, utilizing a powerful platform that combines computational biology and artificial intelligence [1]. Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, a year-over-year decrease of 99.43% [1]. - The company recorded a net profit attributable to shareholders of -$33,424,100, reflecting a year-over-year decline of 76.41% [1]. Company Overview - Tianyan Pharmaceuticals is a platform-driven biopharmaceutical company in the clinical product development stage, dedicated to discovering and developing new cancer immunotherapies [1]. - The company’s antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, aiming to create potentially innovative or best-in-class products globally [1].

Core Viewpoint - Tianyan Pharmaceuticals (ADAG) has experienced a significant stock price increase of 11.52%, reaching $2.42 per share, with a total market capitalization of $114 million, despite facing a substantial decline in revenue and net profit [1]. Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, a year-over-year decrease of 99.43% [1]. - The company recorded a net loss attributable to shareholders of $33.4241 million, representing a 76.41% decrease compared to the previous year [1]. Company Overview - Tianyan Pharmaceuticals is a biopharmaceutical company focused on the development of clinical products driven by its proprietary platform, specializing in innovative cancer immunotherapies based on original antibodies [1]. - The company utilizes a powerful platform that combines computational biology and artificial intelligence to develop new antibodies with high safety and efficacy, aiming to benefit more cancer patients [1]. - The company's antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, with the goal of creating potentially innovative or best-in-class products globally [1].

资料显示，天演药业公司(纳斯达克股票代码:ADAG)是平台驱动并拥有自主平台产出的临床产品开发阶 段的生物制药公司,公司致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。借助计算生物学和 人工智能相结合的强大平台,公司研制出高安全性和有效性的新型抗体,为更多癌症患者带来了福音。公 司的抗体发现引擎——"动态精准抗体库"(Dynamic Precision Library),正在推动天演药业的产品管线开发, 致力于打造潜在的全球创新或同类最佳型产品。 本文源自：金融界 8月11日，天演药业(ADAG)开盘上涨4.61%，截至21:30，报2.27美元/股，成交9329.0美元，总市值1.07 亿美元。 财务数据显示，截至2024年12月31日，天演药业收入总额10.32万美元，同比减少99.43%；归母净利 润-3342.41万美元，同比减少76.41%。 作者：行情君 ...

Core Viewpoint - The research indicates that dietary galactose can reprogram hepatocytes to produce insulin-like growth factor binding protein-1 (IGFBP-1), which prevents T cell exhaustion and stimulates antitumor immune responses [2][3][5]. Group 1: Research Findings - High galactose diets promote hepatocytes to produce IGFBP-1, inhibiting T cell exhaustion dependent on insulin-like growth factor-1 (IGF-1) signaling [5]. - The absence of IGF-1 receptor (IGF-1R) in T cells enhances antitumor CD8+ T cell responses and prevents T cell exhaustion, demonstrating a phenotype associated with high galactose feeding [5]. - Galactose in the circulatory system reprograms hepatocyte metabolism, inhibiting mTORC1 activity and inducing IGFBP-1 production to enhance CD8+ T cell function [5]. Group 2: Clinical Observations - In cancer patients, those with higher plasma levels of IGFBP-1 exhibited reduced T cell exhaustion and enhanced T cell responses in tumor tissues [5]. - These findings suggest that dietary galactose can specifically stimulate robust antitumor CD8+ T cell responses, providing new insights for developing more effective cancer immunotherapies [5].

Core Insights - Tianyan Pharmaceutical (ADAG) experienced a stock price increase of 2.82%, reaching $2.241 per share with a total market capitalization of $106 million as of August 8 [1] - The company's financial data indicates a total revenue of $103,200 as of December 31, 2024, representing a year-over-year decrease of 99.43%, while the net profit attributable to shareholders was -$33.4241 million, a decline of 76.41% year-over-year [1] Company Overview - Tianyan Pharmaceutical is a platform-driven biopharmaceutical company focused on the development of clinical products, particularly in the field of cancer immunotherapy based on original antibodies [1] - The company utilizes a powerful platform that combines computational biology and artificial intelligence to develop new antibodies with high safety and efficacy, aiming to provide solutions for cancer patients [1] - The company's antibody discovery engine, known as the "Dynamic Precision Library," is driving the development of its product pipeline, with the goal of creating potentially innovative or best-in-class products globally [1]